October 2018

Cabinet Barny advised Enterome on the conclusion of a global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease.

Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with Enterome's drug candidate EB8018.

Click here for more information.